DekaBank Deutsche Girozentrale lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 429,690 shares of the biotechnology company’s stock after acquiring an additional 30,000 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.14% of Exelixis worth $11,028,000 as of its most recent filing with the SEC.
A number of other hedge funds have also made changes to their positions in EXEL. V Square Quantitative Management LLC bought a new stake in Exelixis during the third quarter worth approximately $30,000. Park Place Capital Corp bought a new stake in shares of Exelixis during the 2nd quarter worth $45,000. GAMMA Investing LLC boosted its holdings in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the period. EntryPoint Capital LLC grew its stake in Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,746 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in Exelixis in the 3rd quarter worth $74,000. Institutional investors and hedge funds own 85.27% of the company’s stock.
Exelixis Stock Performance
Shares of NASDAQ:EXEL opened at $32.44 on Thursday. The company’s fifty day moving average is $26.81 and its 200-day moving average is $24.15. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $33.32. The company has a market capitalization of $9.25 billion, a PE ratio of 27.97, a P/E/G ratio of 0.61 and a beta of 0.54.
Analyst Upgrades and Downgrades
EXEL has been the topic of several research analyst reports. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. BMO Capital Markets increased their price objective on Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research report on Wednesday. Guggenheim raised their price objective on shares of Exelixis from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, The Goldman Sachs Group raised shares of Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.44.
View Our Latest Report on EXEL
Insider Buying and Selling
In other Exelixis news, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total value of $219,120.00. Following the completion of the transaction, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Maria C. Freire sold 8,250 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $26.56, for a total value of $219,120.00. Following the completion of the sale, the director now directly owns 91,007 shares in the company, valued at approximately $2,417,145.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the transaction, the executive vice president now owns 580,325 shares in the company, valued at approximately $16,475,426.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 352,858 shares of company stock worth $9,349,879 in the last three months. Insiders own 2.85% of the company’s stock.
About Exelixis
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Stories
- Five stocks we like better than Exelixis
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.